Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Jul;38(7):1555–1560. doi: 10.1128/aac.38.7.1555

L-651,392, a potent leukotriene inhibitor, controls inflammatory process in Escherichia coli pyelonephritis.

M Tardif 1, D Beauchamp 1, Y Bergeron 1, C Lessard 1, P Gourde 1, M G Bergeron 1
PMCID: PMC284592  PMID: 7979288

Abstract

In this study, the relationship between leukotrienes, peritubular cell infiltration with polymorphonuclear cells (PMNs) and renal tubular damage was investigated in a rat model of acute ascending pyelonephritis. Infection was induced by the injection of 10(5) CFU of Escherichia coli into the bladder and occlusion of the left ureter for 24 h. Treatment of infected animals was started 24 h after the induction of pyelonephritis with either hydrocortisone (25 mg/kg of body weight per day), the leukotriene inhibitor L-651,392 (10 mg/kg/day), or the vehicle of L-651,392 and was maintained for 5 days. At the end of treatment, the animals were killed, serum was collected, and both kidneys were removed for colony counts and histopathology. Renal function was evaluated by the measurement of blood urea nitrogen levels and creatinine clearance. The numbers of PMNs and mononuclear cells (MNs) in the cortex and medulla were recorded for all groups on plastic sections done from the left kidney. Infection alone (vehicle of L-651,392) resulted in intensive interstitial infiltration and a severe tubular destruction in the cortex. Treatment with hydrocortisone did not prevent PMN migration and tissue damage. By contrast, treatment with L-651,392 resulted in a significant reduction in PMNs (P < 0.001 in comparisons with all other groups) and greater preservation of the tubular structure despite identical bacterial counts than in the group receiving hydrocortisone. We conclude that L-651,392 prevents inflammatory cells from reaching the site of infection and protects the kidney from tubular damage associated with inflammation during pyelonephritis. Inhibitors of leukotrienes should be further investigated for their potential benefit as adjuvants to antibiotherapy in the treatment of pyelonephritis.

Full text

PDF
1555

Images in this article

1557Image
on p.1557
1558Image
on p.1558

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ardaillou R., Baud L., Sraer J. Leukotrienes and other lipoxygenase products of arachidonic acid synthesized in the kidney. Am J Med. 1986 Aug 25;81(2B):12–22. doi: 10.1016/0002-9343(86)90904-6. [DOI] [PubMed] [Google Scholar]
  2. Austen K. F. The role of arachidonic acid metabolites in local and systemic inflammatory processes. Drugs. 1987;33 (Suppl 1):10–17. doi: 10.2165/00003495-198700331-00004. [DOI] [PubMed] [Google Scholar]
  3. Badr K. F. 15-Lipoxygenase products as leukotriene antagonists: therapeutic potential in glomerulonephritis. Kidney Int Suppl. 1992 Oct;38:S101–S108. [PubMed] [Google Scholar]
  4. Badr K. F., Kelley V. E., Rennke H. G., Brenner B. M. Roles for thromboxane A2 and leukotrienes in endotoxin-induced acute renal failure. Kidney Int. 1986 Oct;30(4):474–480. doi: 10.1038/ki.1986.210. [DOI] [PubMed] [Google Scholar]
  5. Beauchamp D., Poirier A., Bergeron M. G. Increased nephrotoxicity of gentamicin in pyelonephritic rats. Kidney Int. 1985 Aug;28(2):106–113. doi: 10.1038/ki.1985.128. [DOI] [PubMed] [Google Scholar]
  6. Bergeron M. G., Bastille A., Lessard C., Gagnon P. M. Significance of intrarenal concentrations of gentamicin for the outcome of experimental pyelonephritis in rats. J Infect Dis. 1982 Jul;146(1):91–96. doi: 10.1093/infdis/146.1.91. [DOI] [PubMed] [Google Scholar]
  7. Bergeron M. G., Marois Y. Benefit from high intrarenal levels of gentamicin in the treatment of E. coli pyelonephritis. Kidney Int. 1986 Oct;30(4):481–487. doi: 10.1038/ki.1986.211. [DOI] [PubMed] [Google Scholar]
  8. Bergeron M. G., Trottier S., Lessard C., Beauchamp D., Gagnon P. M. Disturbed intrarenal distribution of gentamicin in experimental pyelonephritis due to Escherichia coli. J Infect Dis. 1982 Sep;146(3):436–439. doi: 10.1093/infdis/146.3.436. [DOI] [PubMed] [Google Scholar]
  9. Bille J., Glauser M. P. Protection against chronic pyelonephritis in rats by suppression of acute suppuration: effect of colchicine and neutropenia. J Infect Dis. 1982 Aug;146(2):220–226. doi: 10.1093/infdis/146.2.220. [DOI] [PubMed] [Google Scholar]
  10. Bresnahan B. A., Wu S., Fenoy F. J., Roman R. J., Lianos E. A. Mesangial cell immune injury. Hemodynamic role of leukocyte- and platelet-derived eicosanoids. J Clin Invest. 1992 Dec;90(6):2304–2312. doi: 10.1172/JCI116118. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Cattell V., Cook H. T., Smith J., Salmon J. A., Moncada S. Leukotriene B4 production in normal rat glomeruli. Nephrol Dial Transplant. 1987;2(3):154–157. [PubMed] [Google Scholar]
  12. Coggeshall J. W., Christman B. W., Lefferts P. L., Serafin W. E., Blair I. A., Butterfield M. J., Snapper J. R. Effect of inhibition of 5-lipoxygenase metabolism of arachidonic acid on response to endotoxemia in sheep. J Appl Physiol (1985) 1988 Sep;65(3):1351–1359. doi: 10.1152/jappl.1988.65.3.1351. [DOI] [PubMed] [Google Scholar]
  13. Cook H. T., Smith J., Salmon J. A., Cattell V. Functional characteristics of macrophages in glomerulonephritis in the rat. O2- generation, MHC class II expression, and eicosanoid synthesis. Am J Pathol. 1989 Feb;134(2):431–437. [PMC free article] [PubMed] [Google Scholar]
  14. Cook J. A., Wise W. C., Halushka P. V. Protective effect of a selective leukotriene antagonist in endotoxemia in the rat. J Pharmacol Exp Ther. 1985 Nov;235(2):470–474. [PubMed] [Google Scholar]
  15. Fischer D. B., Christman J. W., Badr K. F. Fifteen-S-hydroxyeicosatetraenoic acid (15-S-HETE) specifically antagonizes the chemotactic action and glomerular synthesis of leukotriene B4 in the rat. Kidney Int. 1992 May;41(5):1155–1160. doi: 10.1038/ki.1992.176. [DOI] [PubMed] [Google Scholar]
  16. Fisher A. L., Musson D. G., Bayne W. F., Tocco D. J. A sensitive analytical method for the determination of a novel lipoxygenase inhibitor, 4-bromo-2,7-dimethoxy-3H-phenothiazin-3-one, in plasma using reductive electrochemical detection. J Pharm Sci. 1987 Oct;76(10):825–829. doi: 10.1002/jps.2600761016. [DOI] [PubMed] [Google Scholar]
  17. Fussell E. N., Roberts J. A. The ultrastructure of acute pyelonephritis in the monkey. J Urol. 1984 Jul;132(1):179–183. doi: 10.1016/s0022-5347(17)49515-2. [DOI] [PubMed] [Google Scholar]
  18. Garrick R., Wong P. Y. Enzymatic formation and regulatory function of lipoxins and leukotriene B4 in rat kidney mesangial cells. Adv Exp Med Biol. 1991;314:361–369. doi: 10.1007/978-1-4684-6024-7_25. [DOI] [PubMed] [Google Scholar]
  19. Glauser M. P., Francioli P. B., Bille J., Bonard M., Meylan P. Effect of indomethacin on the incidence of experimental Escherichia coli pyelonephritis. Infect Immun. 1983 May;40(2):529–533. doi: 10.1128/iai.40.2.529-533.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Glauser M. P., Lyons J. M., Braude A. I. Prevention of chronic experimental pyelonephritis by suppression of acute suppuration. J Clin Invest. 1978 Feb;61(2):403–407. doi: 10.1172/JCI108951. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Guindon Y., Girard Y., Maycock A., Ford-Hutchinson A. W., Atkinson J. G., Bélanger P. C., Dallob A., DeSousa D., Dougherty H., Egan R. L-651,392: a novel, potent and selective 5-lipoxygenase inhibitor. Adv Prostaglandin Thromboxane Leukot Res. 1987;17A:554–557. [PubMed] [Google Scholar]
  22. Gulbins E., Parekh N., Rauterberg E. W., Schlottmann K., Steinhausen M. Cysteinyl leukotriene actions on the microcirculation of the normal and split hydronephrotic rat kidney. Eur J Clin Invest. 1991 Apr;21(2):184–196. doi: 10.1111/j.1365-2362.1991.tb01808.x. [DOI] [PubMed] [Google Scholar]
  23. Hagmann W., Keppler D. Leukotriene antagonists prevent endotoxin lethality. Naturwissenschaften. 1982 Dec;69(12):594–595. doi: 10.1007/BF00396357. [DOI] [PubMed] [Google Scholar]
  24. Klausner J. M., Paterson I. S., Goldman G., Kobzik L., Rodzen C., Lawrence R., Valeri C. R., Shepro D., Hechtman H. B. Postischemic renal injury is mediated by neutrophils and leukotrienes. Am J Physiol. 1989 May;256(5 Pt 2):F794–F802. doi: 10.1152/ajprenal.1989.256.5.F794. [DOI] [PubMed] [Google Scholar]
  25. Lefkowith J. B., Pippin J., Nagamatsu T., Lee V. Urinary eicosanoids and the assessment of glomerular inflammation. J Am Soc Nephrol. 1992 May;2(11):1560–1567. doi: 10.1681/ASN.V2111560. [DOI] [PubMed] [Google Scholar]
  26. Letts L. G., McFarlane C., Piechuta H., Ford-Hutchinson A. W. Effects of a 5-lipoxygenase inhibitor (L-651,392) and leukotriene D4 antagonist (L-649,923) in two animal models of immediate hypersensitivity reactions. Adv Prostaglandin Thromboxane Leukot Res. 1987;17B:1007–1011. [PubMed] [Google Scholar]
  27. McFarlane C. S., Hamel R., Ford-Hutchinson A. W. Effects of a 5-lipoxygenase inhibitor (L-651,392) on primary and late pulmonary responses to ascaris antigen in the squirrel monkey. Agents Actions. 1987 Oct;22(1-2):63–68. doi: 10.1007/BF01968818. [DOI] [PubMed] [Google Scholar]
  28. McGowan J. E., Jr, Chesney P. J., Crossley K. B., LaForce F. M. Guidelines for the use of systemic glucocorticosteroids in the management of selected infections. Working Group on Steroid Use, Antimicrobial Agents Committee, Infectious Diseases Society of America. J Infect Dis. 1992 Jan;165(1):1–13. doi: 10.1093/infdis/165.1.1. [DOI] [PubMed] [Google Scholar]
  29. Meylan P. R., Glauser M. P. Failure of dexamethasone to prevent polymorphonuclear leukocyte infiltration during experimental acute exudative pyelonephritis and to reduce subsequent chronic scarring. J Infect Dis. 1988 Mar;157(3):480–485. doi: 10.1093/infdis/157.3.480. [DOI] [PubMed] [Google Scholar]
  30. Miller T. E., Findon G., Cawley S., Clarke I. Cellular basis of host defence in pyelonephritis. II. Acute infection. Br J Exp Pathol. 1986 Apr;67(2):191–200. [PMC free article] [PubMed] [Google Scholar]
  31. Miller T., Phillips S. Pyelonephritis: the relationship between infection, renal scarring, and antimicrobial therapy. Kidney Int. 1981 May;19(5):654–662. doi: 10.1038/ki.1981.65. [DOI] [PubMed] [Google Scholar]
  32. Nelson D. H. Corticosteroid-induced changes in phospholipid membranes as mediators of their action. Endocr Rev. 1980 Spring;1(2):180–199. doi: 10.1210/edrv-1-2-180. [DOI] [PubMed] [Google Scholar]
  33. Perico N., Pasini M., Gaspari F., Abbate M., Remuzzi G. Co-participation of thromboxane A2 and leukotriene C4 and D4 in mediating cyclosporine-induced acute renal failure. Transplantation. 1991 Nov;52(5):873–878. doi: 10.1097/00007890-199111000-00023. [DOI] [PubMed] [Google Scholar]
  34. Piper P. J., Stanton A. W., McLeod L. J. The actions of leukotrienes C4 and D4 in the porcine renal vascular bed. Prostaglandins. 1985 Jan;29(1):61–73. doi: 10.1016/0090-6980(85)90151-0. [DOI] [PubMed] [Google Scholar]
  35. Roberts J. A., Roth J. K., Jr, Domingue G., Lewis R. W., Kaack B., Baskin G. Immunology of pyelonephritis in the primate model. V. Effect of superoxide dismutase. J Urol. 1982 Dec;128(6):1394–1400. doi: 10.1016/s0022-5347(17)53516-8. [DOI] [PubMed] [Google Scholar]
  36. Roberts J. A., Roth J. K., Jr, Domingue G., Lewis R. W., Kaack B., Baskin G. Immunology of pyelonephritis in the primate model. VI. Effect of complement depletion. J Urol. 1983 Jan;129(1):193–196. doi: 10.1016/s0022-5347(17)51981-3. [DOI] [PubMed] [Google Scholar]
  37. Rosenthal A., Pace-Asciak C. R. Potent vasoconstriction of the isolated perfused rat kidney by leukotrienes C4 and D4. Can J Physiol Pharmacol. 1983 Apr;61(4):325–328. doi: 10.1139/y83-049. [DOI] [PubMed] [Google Scholar]
  38. Schade U. F., Engel R., Jakobs D. The role of lipoxygenases in endotoxin-induced cytokine production. Prog Clin Biol Res. 1991;367:73–82. [PubMed] [Google Scholar]
  39. Shimamura T. Mechanisms of renal tissue destruction in an experimental acute pyelonephritis. Exp Mol Pathol. 1981 Feb;34(1):34–42. doi: 10.1016/0014-4800(81)90033-2. [DOI] [PubMed] [Google Scholar]
  40. Spaethe S. M., Hsueh W., Needleman P. Pharmacological manipulation of inflammation in rabbit hydronephrosis: effects of a combined cyclooxygenase/lipoxygenase inhibitor ethoxyquin, a thromboxane synthase inhibitor RS-5186 and a PAF antagonist L-659,989. J Pharmacol Exp Ther. 1989 Mar;248(3):1308–1316. [PubMed] [Google Scholar]
  41. Yared A., Albrightson-Winslow C., Griswold D., Takahashi K., Fogo A., Badr K. F. Functional significance of leukotriene B4 in normal and glomerulonephritic kidneys. J Am Soc Nephrol. 1991 Jul;2(1):45–56. doi: 10.1681/ASN.V2145. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES